Recruiting
Major depression
RecruitingInvestigationalNo placebo
Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder
InvestigationalNo placebo
- Disease:Major depression
- Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
Countries:
Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
- Sponsor:Neurocrine Biosciences Inc.



